SCHEDULE: Lantheus Holdings Exits Perspective Therapeutics Stake

Lantheus Holdings, Inc. and its subsidiaries have filed an exit statement, reporting the sale of all remaining shares in Perspective Therapeutics, Inc. and no longer holding a beneficial ownership stake.

Summary

• Lantheus Holdings, Inc. and its subsidiaries (Lantheus Medical Imaging, Inc. and Lantheus Alpha Therapy, LLC) have filed an amendment to their Schedule 13D, marking an exit from their investment in Perspective Therapeutics, Inc.
• The filing indicates that as of November 10, 2026, the Reporting Persons no longer beneficially own any shares of Perspective Therapeutics, Inc. common stock.
• This exit filing follows the sale of 1,000,000 shares on October 5, 2026, at an average price of $2.75 per share, and an additional 3,000,000 shares on November 10, 2026, at an average price of $0.80 per share.
• The total beneficial ownership prior to this exit was 4,739,011 shares, representing 3.9% of the outstanding common stock as of November 4, 2026.
• The number of shares was adjusted to reflect a 1-for-10 reverse stock split effective June 14, 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to the significant reduction in shareholding and the exit filing, indicating a divestment rather than continued investment.

Negatives

• Lantheus Holdings and its subsidiaries have completely divested their stake in Perspective Therapeutics, Inc.
• The sales occurred at prices significantly lower than what might have been expected for a strategic holding, particularly the $0.80 average price on November 10, 2026.
• The filing is an 'exit filing', signifying the end of their investment relationship with the company.

Risks

• The sale of a significant block of shares at a declining price could signal a lack of confidence in Perspective Therapeutics' future prospects by a former major shareholder.
• The exit of a substantial investor may lead to increased downward pressure on Perspective Therapeutics' stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Perspective Therapeutics. It is an exit filing by Lantheus Holdings, indicating their cessation of beneficial ownership.

Management Comments

• To the best knowledge of each of the Reporting Persons, none of the individuals listed on Schedule A to this Statement beneficially owns any of the Issuer's Common Stock.
• The Reporting Persons ceased to be the beneficial owner of more than five percent of the Common Stock on November 10, 2026.
• The filing of this Amendment No. 4 represents the final amendment to the Statement and constitutes an exit filing for the Reporting Persons.

Industry Context

StockSavvy.ai notes that significant share sales by institutional investors, especially when framed as an 'exit filing', can be interpreted as a signal of reduced confidence in the company's future performance or strategic direction within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders of Perspective Therapeutics, Inc. may experience negative price pressure due to the significant sell-off and the signal it sends.
• Potential investors may be deterred by the exit of a former major shareholder, impacting future capital raising efforts for Perspective Therapeutics.
• Creditors of Perspective Therapeutics might view the divestment as a negative indicator of the company's long-term viability.

Next Steps

• Lantheus Holdings and its subsidiaries will no longer hold any shares of Perspective Therapeutics, Inc. common stock.
• Perspective Therapeutics, Inc. will need to address the market perception resulting from the exit of a significant former shareholder.

Key Dates

Recommendation

The complete divestment by Lantheus Holdings, coupled with sales at declining prices and the explicit 'exit filing' status, strongly suggests a lack of confidence in Perspective Therapeutics' future prospects. This indicates a negative outlook for the stock, warranting a sell recommendation.

Keywords

Schedule 13D, Exit Filing, Divestment, Beneficial Ownership, Stock Sale, Lantheus Holdings, Perspective Therapeutics